Tourmaline Bio (TRML) News Today $15.27 +0.16 (+1.06%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$16.75 +1.48 (+9.69%) As of 05/22/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Wexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Wexford Capital LP acquired a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,610 shares of the company's stock, valued at approximMay 22 at 5:34 AM | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LPVelan Capital Investment Management LP raised its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 423,795 shares of the company's stock after purMay 21 at 8:23 AM | marketbeat.comTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 21 at 12:18 AM | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20 at 5:08 PM | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19, 2025 | globenewswire.comContrasting Exelixis (NASDAQ:EXEL) & Tourmaline Bio (NASDAQ:TRML)May 16, 2025 | americanbankingnews.comAnalysts Set Expectations for Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Chardan Capital upped their FY2025 earnings estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Monday, May 5th. Chardan Capital analyst D. Gataulin now forecasts that the company willMay 10, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Tourmaline Bio in a research report issued on Monday, May 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.71)May 10, 2025 | marketbeat.comBrokers Set Expectations for Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for Tourmaline Bio in a research report issued on Sunday, May 4th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.15) peMay 9, 2025 | marketbeat.comQ2 EPS Estimates for Tourmaline Bio Decreased by AnalystTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of Tourmaline Bio in a report issued on Monday, May 5th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.91) for theMay 9, 2025 | marketbeat.comLeerink Partnrs Weighs in on Tourmaline Bio Q2 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Tourmaline Bio in a research note issued to investors on Monday, May 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share ofMay 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Lowers Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Alyeska Investment Group L.P. decreased its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 115,053 shares of the company's stockMay 9, 2025 | marketbeat.comHC Wainwright Weighs in on Tourmaline Bio Q2 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Tourmaline Bio in a research note issued on Monday, May 5th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings oMay 8, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Tourmaline Bio in a report on Monday.May 7, 2025 | marketbeat.comTourmaline Bio's (TRML) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research report on Monday.May 7, 2025 | marketbeat.comTourmaline Bio (TRML) Expected to Announce Earnings on MondayTourmaline Bio (NASDAQ:TRML) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-tourmaline-bio-inc-stock/)May 7, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLCBarclays PLC raised its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 84.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,566 shares of the company's stock after acquiring an additional 26,733 shares dMay 7, 2025 | marketbeat.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comSusquehanna Fundamental Investments LLC Invests $467,000 in Tourmaline Bio, Inc. (NASDAQ:TRML)Susquehanna Fundamental Investments LLC bought a new stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 23,044 shares of the company's stock, vMay 6, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from BrokeragesTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokeraMay 6, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Earnings ResultsTourmaline Bio (NASDAQ:TRML - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.02.May 4, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Acuta Capital Partners LLCAcuta Capital Partners LLC boosted its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 5.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 351,842 shares of the company's stock after buying an additioMay 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 100,139 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)Schonfeld Strategic Advisors LLC grew its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 50.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 298,239 shares of the company's stock afMay 4, 2025 | marketbeat.comTourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 3, 2025 | finanznachrichten.deTourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 2, 2025 | globenewswire.comNantahala Capital Management LLC Lowers Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Nantahala Capital Management LLC trimmed its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 23.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 536,944 shares of the companApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Adage Capital Partners GP L.L.C. bought a new stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 600,000 shares of the company's stock, valuedApril 30, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Position Trimmed by Marshall Wace LLPMarshall Wace LLP cut its stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 16.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,091 shares of the company's stock after selling 22,103 shares during the quApril 29, 2025 | marketbeat.comChardan Capital Weighs in on Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Tourmaline Bio in a research report issued on Wednesday, April 23rd. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings ofApril 29, 2025 | marketbeat.comBlue Owl Capital Holdings LP Sells 451,080 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)Blue Owl Capital Holdings LP trimmed its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 29.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,079,321 shares of the company'sApril 26, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Coverage Initiated at Chardan CapitalChardan Capital assumed coverage on shares of Tourmaline Bio in a research report on Wednesday. They issued a "buy" rating and a $70.00 price target for the company.April 25, 2025 | marketbeat.comTourmaline Bio initiated with a Buy at ChardanApril 23, 2025 | markets.businessinsider.comTourmaline Bio (TRML) Gets a Buy from Chardan CapitalApril 23, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Tourmaline Bio (TRML) with Buy RecommendationApril 23, 2025 | msn.comNan Fung Group Holdings Ltd Acquires 40,290 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)Nan Fung Group Holdings Ltd grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 187,090 shares of the company's stock after purchasing an additional 40,290 shApril 21, 2025 | marketbeat.comHere's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn SituationApril 19, 2025 | finance.yahoo.comVanguard Group Inc. Boosts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Vanguard Group Inc. grew its position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,106,125 shares of the company's stock after purchasinApril 17, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases New Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)American Century Companies Inc. acquired a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 23,357 shares of the company's stock, valuedApril 14, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by BrokeragesShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target prApril 12, 2025 | marketbeat.comTourmaline Bio price target lowered to $63 from $74 at TruistApril 11, 2025 | markets.businessinsider.comPolymer Capital Management HK LTD Acquires Shares of 79,400 Tourmaline Bio, Inc. (NASDAQ:TRML)Polymer Capital Management HK LTD purchased a new stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 79,400 shares of the company's stApril 8, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Pictet Asset Management Holding SA increased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 69.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 419,883 shares of the companyApril 4, 2025 | marketbeat.comTourmaline Bio: We Should Wait For Upcoming Phase 2b Trial DataApril 3, 2025 | seekingalpha.comTruist biotech analyst holds an analyst/industry conference callApril 2, 2025 | markets.businessinsider.comSwiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Swiss National Bank bought a new position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,100 shares of the company's stock, valued at approximately $4March 31, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year priMarch 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at WedbushWedbush upped their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday.March 15, 2025 | marketbeat.comTOURMALINE BIO Earnings Results: $TRML Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comTourmaline Bio (TRML) Gets a Buy from WedbushMarch 15, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright increased their price target on shares of Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a research report on Friday.March 15, 2025 | marketbeat.com Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Media Mentions By Week TRML Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼0.720.69▲Average Medical News Sentiment TRML News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼63▲TRML Articles Average Week Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Disc Medicine News IDEAYA Biosciences News Indivior News Edgewise Therapeutics News Janux Therapeutics News Evotec News Immunocore News Mesoblast News Adaptive Biotechnologies News Vera Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRML Stock Free TRML Stock Alerts